Navigation Links
New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy
Date:6/13/2010

cations for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product.  Further, preclinical results do not guarantee safe and effective performance of product candidates in humans.  The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models.  The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and products liability claims.  We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affectin
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Watson Confirms Renvela® Patent Challenge
2. China Sky One Medical Confirms Continued Sale of Seven of Eight Products on the Ministry of Healths Warning List
3. Publication in Neuropsychopharmacology Confirms CeNeRxs Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A
4. Vivakor Confirms Record Date of Stock Dividend
5. New study confirms exotic electric properties of graphene
6. Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products
7. Analysis confirms that nano-related research has strong multidisciplinary roots
8. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
9. Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts
10. Independent U.S. Study Confirms Veritides Ceeker(TM) Handheld Device Detects Anthrax With Outstanding Accuracy and Reliability
11. Dow AgroSciences Confirms Efficacy of Zinc Finger Nucleases for Precise Genome Modification in Maize
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Pfenex Inc. (NYSE ... the development of biosimilar therapeutics, today announced that ... Global Healthcare Conference in Miami, FL at the Loews Miami ... executive officer of Pfenex, will provide an overview ... on March 12th at 9:00 am ET. A live audio webcast ...
(Date:3/2/2015)... YORK , March 2, 2015 ... scroll to bottom.   Moments ago, Analysts ... including Sunshine Heart (NASDAQ: SSH ), ... ), Syneron Medical (NASDAQ: ELOS ), Spectranetics (NASDAQ: ... ). Analysts Review provides a single unified platform for investors, ...
(Date:3/2/2015)... , March 2, 2015 VG ... developing therapies for autoimmune and infectious diseases, announced ... has issued an important new composition of matter ... through the targeting of CLIP. ... technology underlying VG Life Sciences, VG1177, a synthetic ...
(Date:3/2/2015)... March 02, 2015 Global ... formed alliance with Shenzhen HANK Bioengineering Co., Ltd. ... The alliance will establish a stem cells training ... China in September 2015. , Shenzhen HANK is ... an award-winning scientist, microbiologist and virologist, to integrate ...
Breaking Biology Technology:Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 3Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 4VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3
... BEIJING , June 29 /PRNewswire-Asia-FirstCall/ -- China ... "Company"), a leading organic,compound fertilizer manufacturer and distributor in ... $10 million as a result of the exercise ... IV, L.P. and CAGP IV,Co-Investment, L.P., two affiliates of ...
... June 29 Reportlinker.com announces that a new market ... , , ... Follow-On Biologics: Global Market Outlook 2010-2025 - opportunities and challenges ... , , ...
... "More than meets the eye" may soon become more ... toys. Researchers at Harvard and MIT have reshaped the ... on the ancient art of origami. Called programmable matter ... composed of interconnected triangular sections could transform itself into a ...
Cached Biology Technology:China Agritech, Inc. Receives $10 Million From Warrant Exercise by The Carlyle Group 2China Agritech, Inc. Receives $10 Million From Warrant Exercise by The Carlyle Group 3China Agritech, Inc. Receives $10 Million From Warrant Exercise by The Carlyle Group 4Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 2Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 3Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 4Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 5Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 6Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 7Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 8Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 9Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 10Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 11Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 12Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 13Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 14Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 15Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 16Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 17Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 18Shape-shifting sheets automatically fold into multiple shapes 2
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/11/2015)... February 11, 2015 ... "Access Control Market by Product (Cards and Readers, Biometrics, ... Defense, Government, Industrial, Healthcare, Education) and By Geography - Global ... MarketsandMarkets, the Access Control Market is expected ... at a CAGR of 10.6% between 2014 ...
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... to many men during their fight against prostate cancer can ... The findings were published online this week in a pair ... of Sciences . The results may help explain a ... common treatment for men with advanced prostate cancer, generally keeps ...
... Additional Funding by Syncom Venture Partners and Participation ... GE Security, Baker Capital and Lehman Brothers., NEW ... airport,security, has secured $44.4 million in venture funding. Led ... second investor Syncom Venture,Partners, and existing investors Lockheed Martin, ...
... the U.S. Environmental Protection Agency (EPA) announced the award of ... to investigate how the sizes and shapes of nanoparticles affect ... largest EPA Science to Achieve Results (STAR) grant ever awarded ... single grant ever awarded by EPA STAR for nanotechnology research. ...
Cached Biology News:Why a common treatment for prostate cancer ultimately fails 2Why a common treatment for prostate cancer ultimately fails 3Why a common treatment for prostate cancer ultimately fails 4Clear(R) Secures $44.4 Million in Venture Funding 2Clear(R) Secures $44.4 Million in Venture Funding 3$2M grant awarded to University of Kentucky for research on nanoparticles and human health 2
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
... Inhibitor is a potent noncompetitive ... as RNase A. Like other ... Inhibitor is an acidic protein ... kDa. RNaseOUT inhibits RNase A ...
... Inhibitor (Ribonuclease inhibitor) is a ... to inhibit RNase activity. It ... endonuclease activity. , Inhibits ... RNA template , Lacks ...
Canine Aortic Smooth Muscle Cells (CnAOSMC) (>500,000 cells)...
Biology Products: